| Banner Life Sciences LLC |
69387000101 |
BAFIERTAM 95mg |
2020-09-01 |
5790.0000 |
Specific marketing and pricing plans for Bafiertam™ are not available in the public domain. Generally we plan to market in the US and promote to appropriate healthcare professionals who treat individuals diagnosed with multiple sclerosis.
Marketing: Promotional activities include detailing of the product by sales representatives, limited print distribution and digital resources to health care professionals.
Pricing: As a bioequivalent to Tecfidera, BAFIERTAM™ provides a market-based solution to health care spending with opportunity to deliver cost savings. The US wholesaler acquisition cost (WAC) of $5,790.00, represents a 30% discount to the current WAC of Tecfidera. The WAC is not reflective of discounts and rebates which may be available through Medicaid, Medicare, and commercial insurance. BAFIERTAM™ will also be discounted as required under the 340B program, Federal Supply Schedule, and other government programs. WAC does not include discounts that may be paid on this product to payers, providers, distributors. |
None |
1000000 |
None |
None |
None |
0.0000 |
None |
None |
Drug was developed by Banner Life Sciences, therefore no acquisition data exists
A recently completed (2017) prevalence study, funded by the National MS Society, has estimated that nearly 1 million people over the age of 18 live with a diagnosis of MS. |
None |
| Bionpharma, Inc |
69452016113 |
Deferasirox Oral Tablet Soluble 500 MG |
2020-01-20 |
760.0800 |
Generic drug - Wholesaler Acquisition Cost |
None |
None |
None |
None |
None |
None |
None |
None |
The estimated number of patients is unknown to Bionpharma.
Bionpharma did not acquire this product; these fields are not relevant. |
None |
| Blueprint Medicines Corporation |
72064011030 |
AYVAKIT (avapritinib) Tablets 100 MG, 30 tablets per bottle |
2020-01-16 |
32000.0000 |
None |
1 |
None |
1 |
1 |
None |
None |
None |
None |
Acquisition Cost
Not applicable. Drug was not acquired.
FDA Approval Designation
On January 9, 2020, the U.S. Food and Drug Administration (FDA) approved AYVAKIT™ (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. AYVAKIT has FDA Breakthrough Therapy and Fast Track Designations for the treatment of patients with unresectable or metastatic GIST harboring PDGFRA D842V mutations and was approved under Priority Review.
Expected Utilization
GIST is a rare, genomically driven sarcoma of the gastrointestinal (GI) tract. There are approximately 5,000 patients diagnosed with primary GIST in the U.S. annually, and approximately five to six percent of patients with newly diagnosed GIST have PDGFRA exon 18 mutations. The most common PDGFRA exon 18 mutation is the D842V mutation, which is resistant to all other approved therapies. These incidence estimates are based on external data sources, and GIST epidemiology data are imprecise. We do not have state-specific estimates for anticipated AYVAKIT utilization.
Marketing Plan Disclosure
The company’s marketing plan is not in the public domain nor is this information otherwise publicly available, and therefore, not subject to disclosure.
Pricing Plan Disclosure
The company’s pricing plan is not in the public domain nor is this information otherwise publicly available, and therefore, not subject to disclosure. |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=340 |
| Blueprint Medicines Corporation |
72064012030 |
AYVAKIT (avapritinib) Tablets 200 MG, 30 tablets per bottle |
2020-01-16 |
32000.0000 |
None |
1 |
None |
1 |
1 |
None |
None |
None |
None |
Acquisition Cost
Not applicable. Drug was acquired.
FDA Approval Designation
On January 9, 2020, the U.S. Food and Drug Administration (FDA) approved AYVAKIT™ (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. AYVAKIT has FDA Breakthrough Therapy and Fast Track Designations for the treatment of patients with unresectable or metastatic GIST harboring PDGFRA D842V mutations and was approved under Priority Review.
Expected Utilization
GIST is a rare, genomically driven sarcoma of the gastrointestinal (GI) tract. There are approximately 5,000 patients diagnosed with primary GIST in the U.S. annually, and approximately five to six percent of patients with newly diagnosed GIST have PDGFRA exon 18 mutations. The most common PDGFRA exon 18 mutation is the D842V mutation, which is resistant to all other approved therapies. These incidence estimates are based on external data sources, and GIST epidemiology data are imprecise. We do not have state-specific estimates for anticipated AYVAKIT utilization.
Marketing Plan Disclosure
The company’s marketing plan is not in the public domain nor is this information otherwise publicly available, and therefore, not subject to disclosure.
Pricing Plan Disclosure
The company’s pricing plan is not in the public domain nor is this information otherwise publicly available, and therefore, not subject to disclosure. |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=341 |
| Blueprint Medicines Corporation |
72064013030 |
AYVAKIT (avapritinib) Tablets 300 MG, 30 tablets per bottle |
2020-01-16 |
32000.0000 |
None |
1 |
None |
1 |
1 |
None |
None |
None |
None |
Acquisition Cost
Not applicable. Drug was not acquired.
FDA Approval Designation
On January 9, 2020, the U.S. Food and Drug Administration (FDA) approved AYVAKIT™ (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. AYVAKIT has FDA Breakthrough Therapy and Fast Track Designations for the treatment of patients with unresectable or metastatic GIST harboring PDGFRA D842V mutations and was approved under Priority Review.
Expected Utilization
GIST is a rare, genomically driven sarcoma of the gastrointestinal (GI) tract. There are approximately 5,000 patients diagnosed with primary GIST in the U.S. annually, and approximately five to six percent of patients with newly diagnosed GIST have PDGFRA exon 18 mutations. The most common PDGFRA exon 18 mutation is the D842V mutation, which is resistant to all other approved therapies. These incidence estimates are based on external data sources, and GIST epidemiology data are imprecise. We do not have state-specific estimates for anticipated AYVAKIT utilization.
Marketing Plan Disclosure
The company’s marketing plan is not in the public domain nor is this information otherwise publicly available, and therefore, not subject to disclosure.
Pricing Plan Disclosure
The company’s pricing plan is not in the public domain nor is this information otherwise publicly available, and therefore, not subject to disclosure. |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=342 |
| Blueprint Medicines Corporation |
72064021060 |
GAVRETO (pralsetinib) Capsule Bottle of 60 100MG |
2020-09-08 |
9621.6000 |
None |
1 |
2946 |
1 |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=446 |
| Blueprint Medicines Corporation |
72064021090 |
GAVRETO (pralsetinib) Capsule Bottle of 90 100MG |
2020-09-08 |
14432.4000 |
None |
1 |
2946 |
1 |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=445 |
| Bristol Myers Squibb |
59572082030 |
ZEPOSIA ® (ozanimod) 0.92 mg 30 count bottle |
2020-06-01 |
7068.4900 |
We consider multiple factors when setting a list price for a medicine, including:
• The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
• Market and business considerations, including:
• Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
• Medical- and patient-service costs; this includes funding growing patient assistance programs;
• Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
280000 |
None |
None |
2019-11-20 |
74000000000.0000 |
None |
BMS obtained rights for Zeposia as part of Celgene acquisition. This acquisition did not consist of costs for individual assets |
Total class of RRMS (Relapsing-remitting multiple sclerosis) and SPMS (Secondary-progressive multiple sclerosis) is estimated at 280,000 patients. BMS is unable to provide an estimate of the number of patients who will be prescribed Zeposia each month |
None |
| Bristol Myers Squibb |
59572089091 |
ZEPOSIA ® (ozanimod) starter kit (7 day titration pack + 0.92 mg 30 count bottle) |
2020-06-01 |
8717.8100 |
We consider multiple factors when setting a list price for a medicine, including:
• The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
• Market and business considerations, including:
• Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
• Medical- and patient-service costs; this includes funding growing patient assistance programs;
• Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
280000 |
None |
None |
2019-11-20 |
74000000000.0000 |
None |
BMS obtained rights for Zeposia as part of Celgene acquisition. This acquisition did not consist of costs for individual assets |
Total class of RRMS (Relapsing-remitting multiple sclerosis) and SPMS (Secondary-progressive multiple sclerosis) is estimated at 280,000 patients. BMS is unable to provide an estimate of the number of patients who will be prescribed Zeposia each month |
None |
| Bristol Myers Squibb |
59572081007 |
ZEPOSIA® (ozanimod) 7 day titration pack |
2020-06-01 |
1649.3200 |
We consider multiple factors when setting a list price for a medicine, including:
• The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
• Market and business considerations, including:
• Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
• Medical- and patient-service costs; this includes funding growing patient assistance programs;
• Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
280000 |
None |
None |
2019-11-20 |
74000000000.0000 |
None |
BMS obtained rights for Zeposia as part of Celgene acquisition. This acquisition did not consist of costs for individual assets |
Total class of RRMS (Relapsing-remitting multiple sclerosis) and SPMS (Secondary-progressive multiple sclerosis) is estimated at 280,000 patients. BMS is unable to provide an estimate of the number of patients who will be prescribed Zeposia each month |
None |
| Bristol Myers Squibb |
59572073014 |
ONUREG® (azacitidine) 200mg 14 count bottle |
2020-09-04 |
21158.1100 |
We consider multiple factors when setting a list price for a medicine, including:
• The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
• Market and business considerations, including:
• Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
• Medical- and patient-service costs; this includes funding growing patient assistance programs;
• Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
2700 |
None |
1 |
2019-11-20 |
74000000000.0000 |
None |
BMS obtained rights for Onureg as part of Celgene acquisition. This acquisition did not consist of costs for individual assets |
Total class of AML (Acute Myeloid Leukemia) is estimated at 18,000 patients. At peak, average monthly number of patients who will be prescribed with Onureg is estimated at 2,700. |
None |
| Bristol Myers Squibb |
59572074014 |
ONUREG® (azacitidine) 300mg 14 count bottle |
2020-09-04 |
21158.1100 |
We consider multiple factors when setting a list price for a medicine, including:
• The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
• Market and business considerations, including:
• Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
• Medical- and patient-service costs; this includes funding growing patient assistance programs;
• Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
2700 |
None |
1 |
2019-11-20 |
74000000000.0000 |
None |
BMS obtained rights for Onureg as part of Celgene acquisition. This acquisition did not consist of costs for individual assets |
Total class of AML (Acute Myeloid Leukemia) is estimated at 18,000 patients. At peak, average monthly number of patients who will be prescribed with Onureg is estimated at 2,700. |
None |